PBT2 rapidly improves cognition in alzheimer's disease: Additional phase II analyses

Journal of Alzheimer's Disease

Volumn 20, Issue 2, 2010, Pages 509-516

  Faux, Noel G ^a   Ritchie, Craig W ^b   Gunn, Adam ^a   Rembach, Alan ^a,c   Tsatsanis, Andrew ^a   Bedo, Justin ^c   Harrison, John ^d   Lannfelt, Lars ^e   Blennow, Kaj ^f   Zetterberg, Henrik ^f   Ingelsson, Martin ^e   Masters, Colin L ^a   Tanzi, Rudolph E ^g   Cummings, Jeffrey L ^h   Herd, Caroline M ⁱ   Bush, Ashley I ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c CSIRO   (Australia)

^d National ICT of Australia ^*  (United Kingdom)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Prana Biotechnology   (Australia)

Author keywords

Alzheimer's disease; clinical trials Randomized controlled; cognition; PBT2

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CERULOPLASMIN; COPPER ZINC SUPEROXIDE DISMUTASE; IONOPHORE; NOOTROPIC AGENT; OXIDOREDUCTASE; PBT 2; PLACEBO; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; COGNITION; CONTROLLED STUDY; COPPER BLOOD LEVEL; DRUG EFFECT; HUMAN; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 77954344206     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1390     Document Type: Article

References (19)

1. Bush AI (2008) Drug development based on the metals hypothesis of Alzheimer's disease. J Alzheimers Dis 15, 223-240.
2. Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, Laughton K, Li QX, Charman SA, Nicolazzo JA, Wilkins S, Deleva K, Lynch T, Kok G, Ritchie CW, Tanzi RE, Cappai R, Masters CL, Barnham KJ, Bush AI (2008) Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59, 43-55.
3. Bush AI, Tanzi RE (2008) Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 5, 421-432.
4. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7, 779-786.
5. McKhann G, Drachman D, Folstein MF, Katzman R, Price D, Stadlen E (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
6. RDevelopmentCoreTeam (2009) R: A Language and Environment for Statistical Computing.
7. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 57, 289-300.
8. Brumback LC, Pepe MS, Alonzo TA (2006) Using the ROC curve for gauging treatment effect in clinical trials. Stat Med 25, 575-590.
9. Schosinsky KH, Lehmann HP, Beeler MF (1974) Measurement of ceruloplasmin from its oxidase activity in serum by use of o-dianisidine dihydrochloride. Clin Chem 20, 1556-1563.
10. Peskin AV, Winterbourn CC (2000) A microtiter plate assay for superoxide dismutase using a water-soluble tetrazolium salt (WST-1). Clin Chim Acta 293, 157-166.
11. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 50, 136-145.
12. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny RA, Li QX, Tammer A, Carrington D,Mavros C,Volitakis I, XilinasM, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting A? amyloid deposition and toxicity in Alzheimer's disease: a pilot phase 2 clinical trial. Arch Neurol 60, 1685-1691.
13. Squitti R, Pasqualetti P, Dal Forno G, Moffa F, Cassetta E, Lupoi D, Vernieri F, Rossi L, Baldassini M, Rossini PM (2005) Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology 64, 1040-1046.
14. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttila T, Wallin A, Jonhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385-393.
15. Aisen PS, Gauthier S, Vellas B, Briand R, Saumier D, Laurin J, Garceau D (2007) Alzhemed: a potential treatment for Alzheimer's disease. Curr Alzheimer Res 4, 473-478. (Pubitemid 47416642)
16. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 2061-2070.
17. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH, for the Tarenflurbil Phase 3 Study Group (2009) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302, 2557-2564.
18. Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M (2007) A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol 64, 1323-1329.
19. Black R, Harrison J, Li D, Yang L, Booth K, Barlas S (2009). A Comparison of the Neuropsychological Test Battery (NTB) and ADAS-Cog Based on Alzheimerfls Disease Clinical Trials. In: International Conference on Alzheimer' s Disease. Vienna, P4-089.